Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines

Szu Chun Hung, Ko Lin Kuo, Der Cherng Tarng, Chih Cheng Hsu, Mai Szu Wu, Tung Po Huang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit

Original languageEnglish
Pages (from-to)735-739
Number of pages5
JournalNephrology
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 1 2014
Externally publishedYes

    Fingerprint

Keywords

  • anaemia
  • chronic kidney disease
  • erythropoietin
  • iron
  • Taiwan

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Hung, S. C., Kuo, K. L., Tarng, D. C., Hsu, C. C., Wu, M. S., & Huang, T. P. (2014). Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology, 19(12), 735-739. https://doi.org/10.1111/nep.12332